




RealRate

ADVERTISING 2017

US China Biomedical Technology Inc
Rank 28 of 28



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of US China Biomedical Technology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of US China Biomedical Technology Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 0.12% points. The greatest weakness of US China Biomedical Technology Inc is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.12%, being 81% points below the market average of 81%.

Input Variable	Value in 1000 USD
Assets, Current	0
Assets, Non-Current	0
Cost of Goods and Services Sold	0
General and Administrative Expense	56
Intangible Assets	0
Liabilities, Current	31
Liabilities, Non-Current	0
Marketing and Selling Expenses	0
Other Assets	2.9
Other Compr. Net Income	0
Other Expenses	0.80
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property, Plant and Equipment	0

Output Variable	Value in 1000 USD
Assets	2.9
Liabilities	31
Expenses	57
Revenues	0
Stockholders Equity	-28
Net Income	-57
Comprehensive Net Income	-57
ECR before Limited Liability	-469%
Economic Capital Ratio	0.12%